Show simple item record

dc.contributor.authorDe Fusco, C
dc.contributor.authorBrear, P
dc.contributor.authorIegre, J
dc.contributor.authorGeorgiou, KH
dc.contributor.authorSore, HF
dc.contributor.authorHyvönen, M
dc.contributor.authorSpring, DR
dc.date.accessioned2017-08-15T10:49:12Z
dc.date.available2017-08-15T10:49:12Z
dc.date.issued2017-07-01
dc.identifier.issn0968-0896
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/266383
dc.description.abstractRecently we reported the discovery of a potent and selective CK2α inhibitor CAM4066. This compound inhibits CK2 activity by exploiting a pocket located outside the ATP binding site (αD pocket). Here we describe in detail the journey that led to the discovery of CAM4066 using the challenging fragment linking strategy. Specifically, we aimed to develop inhibitors by linking a high-affinity fragment anchored in the αD site to a weakly binding warhead fragment occupying the ATP site. Moreover, we describe the remarkable impact that molecular modelling had on the development of this novel chemical tool. The work described herein shows potential for the development of a novel class of CK2 inhibitors.
dc.description.sponsorshipThis work was funded by the Wellcome Trust Strategic (090340/Z/09/Z) and Pathfinder (107714/Z/15/Z) Awards. The Spring lab acknowledges support from the European Research Council under the European Union’s Seventh Framework Programme (FP7/2007-2013)/ERC grant agreement no [279337/DOS]. In addition, the group research was supported by grants from the Engineering and Physical Sciences Research Council, Biotechnology and Biological Sciences Research Council, Medical Research Council, Royal Society and Welcome Trust.
dc.languageeng
dc.language.isoen
dc.publisherElsevier
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectCK2
dc.subjectFragment-based drug discovery
dc.subjectKinase inhibition
dc.subjectFragment linking
dc.subjectMolecular modelling
dc.titleA fragment-based approach leading to the discovery of a novel binding site and the selective CK2 inhibitor CAM4066
dc.typeArticle
prism.endingPage3482
prism.issueIdentifier13
prism.publicationDate2017
prism.publicationNameBioorganic and Medicinal Chemistry
prism.startingPage3471
prism.volume25
dc.identifier.doi10.17863/CAM.12614
dcterms.dateAccepted2017-04-27
rioxxterms.versionofrecord10.1016/j.bmc.2017.04.037
rioxxterms.versionAM
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
rioxxterms.licenseref.startdate2017-07-01
dc.contributor.orcidIegre, Jessica [0000-0002-9074-653X]
dc.contributor.orcidSore, Hannah [0000-0002-6542-0394]
dc.contributor.orcidSpring, David [0000-0001-7355-2824]
dc.identifier.eissn1464-3391
rioxxterms.typeJournal Article/Review
pubs.funder-project-idEngineering and Physical Sciences Research Council (EP/J016012/1)
pubs.funder-project-idWellcome Trust (090340/Z/09/Z)
pubs.funder-project-idEngineering and Physical Sciences Research Council (EP/K039520/1)
pubs.funder-project-idEngineering and Physical Sciences Research Council (EP/P020291/1)
pubs.funder-project-idWellcome Trust (107714/Z/15/Z)
pubs.funder-project-idEuropean Research Council (279337)
cam.issuedOnline2017-04-30
rioxxterms.freetoread.startdate2018-04-30


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 International
Except where otherwise noted, this item's licence is described as Attribution-NonCommercial-NoDerivatives 4.0 International